ADNI4 builds on the extensive history of the study but aims to make ADNI data more broadly relevant and generalizable to the North American population. ADNI4 continues to aid in the discovery, optimization, standardization, and validation of clinical trial measures and biomarkers used in AD research. ADNI4 began enrolling participants in 2023.
New assessments to help understand social determinants of health including:
ADNI4 also incorporates novel “remote cohorts” which includes screening participants from their home and referring those likely to be eligible to participate in the ADNI4 clinical based study to their local site.
The results from the participants in these remote cohorts will also be shared on the LONI data repository.
Data collected from participants completing online questionnaires and cognitive testing (Remote Digital Cohort), coupled with blood-based biomarkers (Remote Blood Cohort), will identify individuals who will be referred to ADNI4 clinical sites for in-depth clinical, imaging, genetic, and biochemical biomarker characterization.
In-clinic participants in the cognitively unimpaired (CU) and mild cognitive impairment (MCI) arms of the study are invited to complete cognitive assessments through an online portal.
If you are 55 to 90 years of age you may be able to participate. Participation is free and no medication is involved.
Join
